Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| ZP 1609 | ZP 1609, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, which is confirmed in phase I clinical trials. It is used for the treatment of atrial fibrillation. It improves conduction and reduces atrial fibrillation or flutter in the canine sterile pericarditis model. It prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. It showed consistent efficacy on measures of conduction and AF/AFL inducibility in the canine sterile pericarditis model. It was developed by Zealand Pharma and was termination in Clinical phase II. Uses: Zp 1609 is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy. it is used for the treatment of atrial fibrillation. Synonyms: GAP-134; GAP 134; GAP134; ZP-1609; ZP1609; ZP 1609; (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid;Danegaptide. Grades: >98 %. CAS No. 943134-39-2. Molecular formula: C14H17N3O4. Mole weight: 291.30. |  |
| ZP 1609 Hydrochloride | ZP 1609 Hydrochloride is the hydrochloride form of ZP 1609, which is a small modified dipeptide and has been identified as a potent and selective second generation gap junction modifier with oral bioavailability. It is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy, which is confirmed in phase I clinical trials. It is used for the treatment of atrial fibrillation. It was developed by Zealand Pharma and was termination in Clinical phase II. Uses: Zp 1609 hydrochloride is a pharmalogical agent with a favorable clinical safety profile and potential antiarrhythmic efficacy. it is used for the treatment of atrial fibrillation. Synonyms: Danegaptide Hydrochloride;GAP 134 Hydrochloride;(4R)-Glycyl-4-(benzoylamino)-L-proline hydrochloride (1:1);ZP-1609 Hydrochloride; ZP 1609 Hydrochloride; ZP1609 Hydrochloride; (2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic Acid Hydrochloride. Grades: >98 %. CAS No. 943133-81-1. Molecular formula: C14H18ClN3O4. Mole weight: 327.76. | |
Our database is helping our users find suppliers everyday.
